Cadrenal Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CVKD Nasdaq 2836 www.cadrenal.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Mar 13th, 2025 8:05 pm
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial… - Mar 7th, 2025 1:15 pm
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Mar 5th, 2025 12:28 pm
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - Mar 4th, 2025 1:00 pm
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Feb 6th, 2025 2:00 pm
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - Feb 5th, 2025 2:00 pm
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Jan 9th, 2025 1:44 pm
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Dec 31st, 2024 1:00 pm
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Dec 18th, 2024 2:00 pm
CVKD: Recent Financings Raise $9.8 Million… - Nov 20th, 2024 1:03 pm
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - Nov 19th, 2024 2:00 pm
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS - Nov 12th, 2024 2:00 pm
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE - Nov 7th, 2024 2:00 pm
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds - Nov 2nd, 2024 12:00 am
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate - Oct 28th, 2024 12:26 pm
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - Oct 24th, 2024 1:00 pm
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM - Oct 23rd, 2024 1:00 pm
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference - Sep 23rd, 2024 8:15 pm
CVKD: New Blood Thinner Ready for Phase 3; Initiating Coverage of Cadrenal Therapeutics, Inc… - Sep 16th, 2024 9:22 am
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Sep 11th, 2024 5:00 pm